An Open-label Study That Will Test a Second Treatment Session of RZL-012.
NCT05763160
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Submental Fat
Interventions
DRUG:
RZL-012
Sponsor
Raziel Therapeutics Ltd.